A Rollover Protocol to Provide Open-Label Emtricitabine/Tenofovir Disoproxil Fumarate Combination Product to Subjects Completing the GS-US-203-0107 Study. Protocol GS-US-203-0109

ID Number 09-2183

Principal Investigator(s)
Thomas D. Schiano

Department(s) or Division(s)
Liver Diseases

Description

Gilead is offering an extension protocol providing Truvada (tenofovir) to all interested subjects who complete 96 weeks of the GS-US-203-0107 study (GCO 07-0571). The duration of this protocol will be 5 years.

Contact Information
Yasir Qureshi
(212) 659-8041
yasir.qureshi@mountsinai.org


Recruiting Patients: Yes